Furthermore, we have demonstrated in vitro efficacy of NIC-hLYS reducing complications related to COVID-19, most notably secondary bacterial pneumonia by MRSA and dampening (but not complete suppression) of TNF-α and IL-6, which are known markers for COVID-19 disease severity [81]. The gene discussed is IL6; the disease is bacterial pneumonia.